A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction.
ABSTRACT We sought to determine whether maca, a Peruvian plant, is effective for selective-serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction. We conducted a double-blind, randomized, parallel group dose-finding pilot study comparing a low-dose (1.5 g/day) to a high-dose (3.0 g/day) maca regimen in 20 remitted depressed outpatients (mean age 36+/-13 years; 17 women) with SSRI-induced sexual dysfunction. The Arizona Sexual Experience Scale (ASEX) and the Massachusetts General Hospital Sexual Function Questionnaire (MGH-SFQ) were used to measure sexual dysfunction. Ten subjects completed the study, and 16 subjects (9 on 3.0 g/day; 7 on 1.5 g/day) were eligible for intent-to-treat (ITT) analyses on the basis of having had at least one postbaseline visit. ITT subjects on 3.0 g/day maca had a significant improvement in ASEX (from 22.8+/-3.8 to 16.9+/-6.2; z=-2.20, P=0.028) and in MGH-SFQ scores (from 24.1+/-1.9 to 17.0+/-5.7; z=-2.39, P=0.017), but subjects on 1.5 g/day maca did not. Libido improved significantly (P<0.05) for the ITT and completer groups based on ASEX item #1, but not by dosing groups. Maca was well tolerated. Maca root may alleviate SSRI-induced sexual dysfunction, and there may be a dose-related effect. Maca may also have a beneficial effect on libido.
SourceAvailable from: Anita Clayton[Show abstract] [Hide abstract]
ABSTRACT: There is a well-established relationship between sexual functioning and quality of life. Depression can cause sexual dysfunction (SD) and its treatment can often lead to restoration of sexual functioning. Use of antidepressants has also been associated with SD, with implications for treatment compliance and creation of further distress for the patient. This review evaluates available information regarding SD related to both depression and antidepressant treatment, including literature up to June 2014. It includes eligible published studies that investigated antidepressant-associated SD (AASD). Expert opinion: Depression and SD have a bidirectional association. When screening for depression, baseline sexual functioning should be assessed with validated rating scales. If sexual side effects develop with antidepressant treatment, management options include waiting for spontaneous remission, decreasing the medication dose, switching to an alternative drug or adding an augmentation agent or antidote. Research suggests that bupropion and newer antidepressants exhibit a more favorable SD profile compared with other antidepressants, especially selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors. Bupropion, mirtazapine and buspirone have been studied as augmentation agents/antidotes or substitution agents in management of AASD. Future studies validating genetic factors could enable personal genotyping to guide individualized treatment and also facilitate the development of enhanced therapeutic guidelines to avoid or manage AASD.Expert Opinion on Drug Safety 08/2014; 13(10):1-14. DOI:10.1517/14740338.2014.951324 · 2.74 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Maca (Lepidium meyenii) is a tuber root plant of the Brassicaceae family that grows on Andes mountain’s high altitude steps. Its tuber roots have rich nutrition contents and bioactive compounds as sterols, glucosinolates, alkaloids, alkamides (macaene, macamides), saponin and tanin. Beside of its traditional usage, the studies in recent years presented its capabilities that are energizer, aphrodisiac, improving reproduction, hormonal balancing, improving homeostasis, antioksidant, anticarcinogen and antistress. When Maca was used as a dietary additive at the many researches in humans and animals, no toxic effect was determined. Further studies are required to identify the compounds of Maca, their chemical structures, the mechanism of action and to use of Maca as a safe and natural feed additive in animal nutrition.
Journal of psychiatry & neuroscience: JPN 09/2013; 38(5):E27-8. DOI:10.1503/jpn.130076 · 7.49 Impact Factor